le vendredi 19 octobre 2018, à 20:31. Posté
par Shannon
Just over two years https://avang.ir/med-pubcomajm-385d.pdf med-pub.com/apmr Prosensa has fared better than Belgium's Cardio3 BioSciences, which priced its initial public offering in Europe in early July at the bottom of its hoped-for range and took a further knock from questions over its research, which it said were unfounded.